A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )

PHASE2CompletedINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

Not specified

Conditions
Cytomegalovirus RetinitisHIV Infections
Interventions
DRUG

Fomivirsen sodium

DRUG

Ganciclovir

Trial Locations (18)

10028

Vitreo - Retinal Consultants, New York

19102

Hahnemann Univ Hosp, Philadelphia

23507

Virginia Eye Consultants, Norfolk

28204

Charlotte Eye Ear Nose and Throat Association, Charlotte

30327

Georgia Retina, Atlanta

33060

Dr Julio Perez, Fort Lauderdale

46202

Indiana Univ Med Ctr, Indianapolis

60612

Univ of Illinois, Chicago

77030

Baylor College of Medicine, Houston

80262

Univ of Colorado Health Sciences Ctr, Denver

90017

Retina - Vitreous Associates Med Group, Los Angeles

92134

San Diego Naval Hosp, San Diego

94110

Univ of California San Francisco / SF Gen Hosp, San Francisco

95128

Santa Clara Valley Med Ctr, San Jose

98104

Novum Inc, Seattle

191461192

Graduate Hosp, Philadelphia

752359057

Univ of Texas Southwestern Med Ctr of Dallas, Dallas

911052536

Community Eye Med Group, Pasadena

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY

NCT00002156 - A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR ) | Biotech Hunter | Biotech Hunter